Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Other Non-Current Liabilities (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Other Non-Current Liabilities for 5 consecutive years, with $38000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 93.27% to $38000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $38000.0 through Dec 2025, down 93.27% year-over-year, with the annual reading at $38000.0 for FY2025, 93.27% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $38000.0 at Mereo BioPharma, down from $336000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $925000.0 in Q2 2024, with the low at $30000.0 in Q4 2023.
  • Average Other Non-Current Liabilities over 4 years is $389284.1, with a median of $377500.0 recorded in 2025.
  • The sharpest move saw Other Non-Current Liabilities tumbled 99.84% in 2021, then skyrocketed 1783.33% in 2024.
  • Over 4 years, Other Non-Current Liabilities stood at $107840.9 in 2021, then crashed by 72.18% to $30000.0 in 2023, then surged by 1783.33% to $565000.0 in 2024, then crashed by 93.27% to $38000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $38000.0, $336000.0, and $545000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.